Australia GLP-1 guide: TGA, PBS, and the Eucalyptus duopoly
Australian access is dominated by Eucalyptus (Pilot, Juniper) running an asynchronous multidisciplinary model. Weight loss is fully private (no PBS reimbursement); diabetes has PBS coverage for Ozempic. Here’s how the system works.
PBS vs private — what you pay
PBS-funded (Authority Required)
- Eligibility: Type 2 diabetes only
- Cost: AU$32 per script (concessional AU$7.70)
- Medications: Ozempic, Mounjaro (T2D indication)
- Weight loss not covered under PBS
- GP can prescribe; specialist often not required
Private route
- Eligibility: BMI ≥30 (or ≥27 with comorbidity) typically
- Cost: AU$420-565/month
- Medications: Wegovy (weight loss), Mounjaro (weight loss off-label)
- Async MDT model dominant (Eucalyptus)
- Wait: 48-96 hours
Australian telehealth providers
| Provider | Monthly | Model | Notes |
|---|---|---|---|
| Pilot (Eucalyptus) | AU$429-565 | Async MDT (GP + dietitian) | Male-only at launch, all-gender from 2024. Largest AU telehealth. |
| Juniper (Eucalyptus) | AU$429-565 | Async MDT | Female-focused brand. Same Eucalyptus medical infrastructure as Pilot. |
| Mosh | AU$420-510 | Async + optional video | Wesfarmers-backed. PBS-aware intake. |
| Hub Health | AU$435-545 | Video consult required | Synchronous model. Bulk-billed in some regions. |
Check your BMI
BMI calculator
BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).
BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.
FAQ
Why does the TGA restrict semaglutide and tirzepatide naming so tightly?
Australia’s Therapeutic Goods Administration enforces strict naming and advertising rules (TGA Code of Conduct for Therapeutic Advertising). Direct-to-consumer pharmaceutical advertising is prohibited — only the molecular/generic name is allowed in patient-facing materials, not brand names like "Wegovy" or "Ozempic" in advertising contexts. This is why most Australian telehealth providers use circumlocutions like "weight-loss injection" or "GLP-1 receptor agonist" in marketing.
What does PBS cover?
The Pharmaceutical Benefits Scheme covers Ozempic (semaglutide) for T2D under Authority Required (Streamlined). For T2D, patients pay $32 (or $7.70 concessional) per script. Wegovy is not PBS-listed — Novo Nordisk has applied but no listing as of May 2026. Mounjaro is PBS-listed for T2D but not weight loss. All weight-loss prescriptions are private (cash retail).
How does the asynchronous MDT model work?
Eucalyptus pioneered the "asynchronous multidisciplinary team" model: patient completes a 20-30 minute intake form online, uploads photos and weight history, and is reviewed by a GP, dietitian, and clinical pharmacist independently. Prescriptions are issued without a real-time video call. Follow-ups are weekly via in-app message. The model is faster for the patient (no scheduling) and lower cost than synchronous video models. Critics argue async limits clinical judgment — but Eucalyptus has published outcome data showing comparable adherence to in-person care.
Can I import semaglutide from overseas into Australia?
Under the Personal Importation Scheme (TGA), individuals may import a 3-month supply of prescription medication for personal use, with a valid prescription from a registered Australian medical practitioner. In practice this is enforced unevenly for GLP-1 medications — Customs has been more aggressive in 2024-2025 due to counterfeiting concerns. Mail-order from US compounders is illegal and seized at the border.
When will generic semaglutide be available in Australia?
Novo Nordisk’s composition-of-matter patent in Australia expires January 2027. Multiple generics manufacturers (Sun Pharma, Sandoz, Apotex) have indicated intent to launch. Expected price drop: 40-60% in the 12 months post-launch. Tirzepatide patents extend further, to 2036+.